Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
Source: View publication →
In patients with muscle-invasive bladder cancer ineligible for or declining cisplatin, perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved event-free and overall survival compared to radical cystectomy alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The VOLGA trial establishes perioperative durvalumab plus neoadjuvant enfortumab vedotin as a highly effective, platinum-free standard-of-care option for patients with muscle-invasive bladder cancer who are ineligible for cisplatin. The robust 49% reduction in the risk of an EFS event and 42% reduction in the risk of death represent a paradigm shift in the management of early-stage, high-risk urothelial carcinoma.
Historical Context
Historically, cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy has been the gold standard for muscle-invasive bladder cancer. However, up to half of patients are ineligible for cisplatin due to renal impairment or other comorbidities, and many proceed directly to surgery, which is associated with high recurrence rates. Following the breakthrough success of enfortumab vedotin plus pembrolizumab in the metastatic setting (EV-302 trial), the VOLGA trial successfully moves this powerful antibody-drug conjugate and immunotherapy strategy into the curative-intent perioperative setting for a high-need patient population.
Guided Discussion
High-yield insights from every perspective
What are the respective mechanisms of action for enfortumab vedotin and durvalumab, and why might combining an antibody-drug conjugate (ADC) with an immune checkpoint inhibitor be synergistic in muscle-invasive bladder cancer?
Key Response
Enfortumab vedotin is an ADC targeting Nectin-4 (highly expressed in urothelial cancer) to deliver MMAE, a microtubule inhibitor. MMAE induces immunogenic cell death, releasing tumor antigens and upregulating costimulatory molecules. Durvalumab is a monoclonal antibody blocking PD-L1, removing the inhibitory signal on T-cells. The ADC-induced tumor microenvironment changes prime the tumor for an enhanced immune response, which is then disinhibited by the checkpoint inhibitor.
When evaluating a patient with newly diagnosed muscle-invasive bladder cancer, what specific clinical criteria define them as 'cisplatin-ineligible,' making them a candidate for this enfortumab vedotin and durvalumab regimen rather than standard neoadjuvant gemcitabine and cisplatin?
Key Response
Cisplatin ineligibility is typically defined by the Galsky criteria: impaired renal function (creatinine clearance less than 60 mL/min), hearing loss (CTCAE grade 2 or higher), peripheral neuropathy (grade 2 or higher), heart failure (NYHA class III/IV), or poor performance status (ECOG 2 or higher). Recognizing these criteria is essential for appropriate patient selection and avoiding life-threatening cisplatin toxicity.
Given the overlapping and distinct toxicities of enfortumab vedotin (severe peripheral neuropathy, severe skin reactions) and durvalumab (immune-related adverse events), how do these toxicities complicate surgical timing, and how should a medical oncologist balance maximizing pathological complete response with the risk of losing the surgical window?
Key Response
Neoadjuvant treatments risk missing the window of curability if toxicities (e.g., severe neuropathy or irAEs requiring prolonged high-dose steroids) delay or preclude radical cystectomy. Fellows must learn to aggressively manage ADC-induced neuropathy and skin toxicity with prompt dose modifications, recognizing that definitive local control via cystectomy remains the cornerstone of curative-intent therapy.
Historically, cisplatin-ineligible patients with muscle-invasive bladder cancer were directed straight to upfront radical cystectomy. With this trial demonstrating unprecedented EFS and OS benefits for neoadjuvant therapy in this population, how does this paradigm shift alter multidisciplinary tumor board dynamics and patient counseling regarding surgical morbidity?
Key Response
This represents a massive paradigm shift, as previous neoadjuvant regimens failed to show a definitive overall survival benefit in cisplatin-ineligible patients. Attendings must now lead multidisciplinary teams to integrate systemic therapy first, requiring careful patient selection to ensure those with borderline performance status do not deteriorate during neoadjuvant EV/durvalumab and lose their surgical candidacy.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The trial utilizes radical cystectomy alone as the control arm for cisplatin-ineligible patients. From a methodological standpoint, how does the absence of biomarker-stratified randomization (e.g., assessing baseline Nectin-4 expression or PD-L1 combined positive score) impact the statistical power and interpretation of treatment heterogeneity?
Key Response
Enrolling an unselected population assumes a universal benefit, but heterogeneous expression of Nectin-4 and PD-L1 could mean the treatment effect is driven by a specific subpopulation. Without baseline biomarker stratification, the trial requires a larger sample size to achieve power, and risks exposing biomarker-negative patients to severe toxicities without guaranteed benefit. Future designs should utilize adaptive biomarker stratification.
As a peer reviewer, how would you critically evaluate the definition, censoring rules, and assessment of 'Event-Free Survival' (EFS) in this open-label perioperative trial, particularly regarding the potential for investigator bias in determining disease progression precluding surgery?
Key Response
In an open-label trial, decisions to cancel or delay surgery, or the interpretation of ambiguous preoperative imaging, can be heavily influenced by knowledge of the treatment arm. A rigorous review would scrutinize whether a Blinded Independent Central Review (BICR) was utilized for progression events and the exact clinical criteria used to declare a patient 'unfit' for surgery, which could artificially inflate EFS events in either arm.
Current NCCN and EAU guidelines traditionally recommend upfront radical cystectomy for cisplatin-ineligible patients with muscle-invasive bladder cancer. Based on the overall survival benefit demonstrated in this trial, how should current guidelines be updated regarding the preferred first-line approach, and what level of evidence does this represent?
Key Response
This study provides Level 1 evidence (randomized phase 3 trial with a positive OS endpoint) for perioperative systemic therapy in cisplatin-ineligible MIBC. Guidelines should be updated to elevate neoadjuvant EV plus durvalumab to a Category 1 preferred recommendation, shifting upfront radical cystectomy to an alternative option reserved primarily for patients who have absolute contraindications to both ADCs and immunotherapy.
Clinical Landscape
Noteworthy Related Trials
CheckMate 274 Trial
Tested
Adjuvant nivolumab for up to 1 year
Population
High-risk muscle-invasive urothelial carcinoma post-surgery
Comparator
Placebo
Endpoint
Disease-free survival
EV-302 / KEYNOTE-A39 Trial
Tested
Enfortumab vedotin plus pembrolizumab
Population
Locally advanced or metastatic urothelial carcinoma
Comparator
Platinum-based chemotherapy
Endpoint
Progression-free survival and overall survival
NIAGARA Trial
Tested
Neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab
Population
Cisplatin-eligible muscle-invasive bladder cancer
Comparator
Neoadjuvant chemotherapy alone
Endpoint
Event-free survival and pathological complete response
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis